Navigation Links
Intarcia Presents Compelling 48-week Results for ITCA 650 - Data Underlines the Promise to Become the First Injection-free GLP-1 Therapy at the 47th Annual EASD Meeting in Lisbon
Date:9/14/2011

diabetes consists of DUROS continuous subcutaneous delivery of exenatide. The DUROS delivery technology comprises the DUROS device, a matchstick-size, miniature osmotic pump that is placed subcutaneously to provide continuous and consistent drug therapy. Intarcia's proprietary formulation technology maintains stability of therapeutic proteins and peptides at human body temperature for extended periods of time.

The DUROS technology can deliver up to a full year of therapy from a single ITCA 650 placement. Unlike other extended delivery technologies, such as polymers or albumin fusions, DUROS delivery provides steady state drug delivery upon placement and allows for near immediate cessation of therapy, if required. ITCA 650 is an investigational new drug and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, has been approved in the U.S., Europe and other markets and is currently marketed as a twice-daily self-injection therapy for type 2 diabetes.  Intarcia's robust worldwide patent portfolio extends protection of ITCA 650 through at least 2027.

About Type 2 Diabetes According to a June 2011 Lancet publication by Danaei and colleagues, an estimated 347 million adults worldwide had diabetes in 2008 and that number is expected to rise to 472 million by 2030.  A significant portion of cases results from striking increases in countries like China and India, accounting for 138 million cases, the US and Russia, accounting for 36 million cases and an additional 42 million cases in Brazil, Pakistan, Indonesia, Japan and Mexico.  Pre-diabetes, or impaired glucose tolerance (IGT), a condition that often leads to diabetes, affects a population that is roughly double the current diabetes population.  The World Health Organization estimates deaths resulting from diabetes will double between 2005 and 2030 and estimates the global cost of diabetes to have exceeded $400 billion in 2010.  U
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
2. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
3. Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
4. Intarcia Therapeutics Executive Chairman Kurt Graves to Present at 29th Annual JP Morgan Healthcare Conference
5. Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... plc (LSE: SHP, NASDAQ: SHPG ) announces that it ... the announced tender offer for all of the outstanding shares of ... the waiver, the transaction is no longer conditional on OFT approval, ... 2014 following the currently scheduled expiration time, subject to the satisfaction ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Medical - SECRITT I Study to Evaluate Preventive Treatment ... Potentially Life Threatening Vulnerable Plaques, ... cardiology team led by Professor Patrick W. Serruys,successfully placed ... coronary artery of a 64-year-old man at Erasmus Medical,Center ...
... -- 10:00 a.m. EDT, 7:00 a.m. PDT ... -- 877-548-7901 ... http://www.isispharm.com , SAN DIEGO, June 30 Isis Pharmaceuticals,(Nasdaq: ISIS ) will conduct a ... TV-1102 clinical trial,and the ATL / TEVA / Isis relationship., -- ATL and TEVA announced clinical ...
Cached Medicine Technology:Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial 2Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial 3Isis Pharmaceuticals Conference Call Notice 2
(Date:4/17/2014)... 2014) Population Council scientists and their partners have found ... can prevent the transmission of multiple sexually transmitted infections ... HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus ... that the gel is effective against multiple strains of ... vagina against all three viruses of at least eight ...
(Date:4/17/2014)... The world is less than 40 years away from ... people and governments, according to a top scientist at ... time in human history, food production will be limited ... water and energy," said Dr. Fred Davies, senior science ... issues could become as politically destabilizing by 2050 as ...
(Date:4/17/2014)... Belfast,s Vice-Chancellor, Professor Patrick Johnston, whose work has transformed ... a Fellow of the European Academy of Cancer Sciences., ... independent advisory body of highly distinguished oncologists and cancer ... caused by cancer in Europe. , Professor Johnston, whose ... move from the bottom of the UK league table ...
(Date:4/16/2014)... April 15, 2014 The Translational Genomics Research Institute ... annual Founders Dinner for their support of TGen,s research ... place March 28 in Scottsdale. , Catherine Ivy, Founder ... received TGen,s John S. McCain Leadership Award, named for ...
(Date:4/16/2014)... that fertility treatments are the leading cause of increases ... risk of premature birth, these results are not inevitable, ... . The article identifies six changes in policy ... births and prematurity, including expanding insurance coverage for in ...
Breaking Medicine News(10 mins):Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3
... Inc. (Nasdaq: SMBL ) announced today Steven Hughes, ... make a presentation at the Roth Capital Partners 21st Annual ... EST on Tuesday, February 17, 2009.Smart Balance,s presentation will be ... be able to ask questions, but listeners to the webcast ...
... from the clinical research community have already pledged ... American National Standards Institute (ANSI), coordinator ... is working to facilitate the use of electronic ... The Institute seeks the active engagement and financial ...
... Feb. 13 Dynatronics Corporation (Nasdaq: DYNT ) ... months ended December 31, 2008. Operating results showed significant improvement ... Pre-tax profit for the quarter ended December 31, 2008, improved ... the second quarter of the prior fiscal year. Net income ...
... BETHESDA, Md., Feb. 13 Micromet, Inc. (Nasdaq: MITI ), ... the ROTH 21st Annual Orange County Growth Stock Conference at the Ritz-Carlton ... The ROTH 21st Annual Orange County Growth Stock Conference, ... 4:30 pm Pacific Time, Place: The Ritz-Carlton ...
... SAN FRANCISCO, Feb. 13, 2009 New techniques used ... in the wild are yielding surprising results about hormones ... the social structure of a broader range of mammals. ... present findings at the AAAS meeting that examine social ...
... Applauds Senator Rockefeller and Representative Filner for Introducing ... Federation of Government Employees (AFGE) today applauded the ... the Senate Committee on Veterans, Affairs and Representative ... Veterans, Affairs for authoring legislation to amend Section ...
Cached Medicine News:Health News:ANSI Seeks Funding to Ensure that Electronic Health Records Will Support Clinical Research Activities 2Health News:ANSI Seeks Funding to Ensure that Electronic Health Records Will Support Clinical Research Activities 3Health News:ANSI Seeks Funding to Ensure that Electronic Health Records Will Support Clinical Research Activities 4Health News:Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results 2Health News:Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results 3Health News:Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results 4Health News:Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference 2Health News:Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference 3Health News:Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference 4Health News:Findings raise new questions about evolution of hormones in mammals 2Health News:Veterans' Affairs Employee Union Urges Congress to Strengthen Collective Bargaining Rights at VA Hospitals 2
... ML1 Manual Lensometer combines the traditional ... advantages, such as LED illumination and ... light source provides a clear green ... operated and completely cordless, the ML1 ...
... The Ultramatic RX Master Phoroptor ... - continues to be the industry standard ... that unmistakable feel of quality. The smooth ... of play in the mechanisms. The precise, ...
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
... The Illuminated Phoroptor features lighted dials ... to perform refractions in the darkened setting ... pen light and leave the lights off ... features lighted sphere, cylinder power and cylinder ...
Medicine Products: